CoChat

Differences in antitumor effects of various statins on human pancreatic cancer

Gbelcová, Helena, Leníček, Martin, Zelenka, Jaroslav, Knejzlík, Zdeněk, Dvořáková, Gabriela, Zadinová, Marie, Poučková, Pavla, Kudla, Michal, Balaž, Peter, Ruml, Tomáš, Vítek, Libor · 2008 · International Journal of Cancer
Cited by 110

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Statins are widely used for the treatment of hypercholesterolemia. However, their inhibitory action on HMG‐CoA reductase also results in the depletion of intermediate biosynthetic products, which importantly contribute to cell proliferation. The aim of the present study was to compare the effects of the individual commercially available statins on experimental pancreatic cancer. The in vitro effects of individual statins (pravastatin, atorvastatin, simvastatin, lovastatin, cerivastatin, rosuvastatin and fluvastatin) on the viability of human pancreatic cancer were evaluated in CAPAN‐2, BxPc‐3 and MiaPaCa‐2 cell lines. The in vivo experiments were performed on nude mice xenotransplanted with CAPAN‐2 cells. The mice received oral treatments either with a placebo, or with the statins mentioned earlier in a daily dose corresponding to a hypocholesterolemic dose in humans. The effect of these statins on the intracellular Ras protein, trafficking in MiaPaCa‐2 transfected cells, was also investigated. Substantial differences in the tumor‐suppressive effects of all statins were detected in both in vitro and in vivo experiments. While simvastatin exerted the highest tumor‐suppressive effects in vitro, rosuvastatin (p = 0.002), cerivastatin (p = 0.002) and fluvastatin (p = 0.009) were the most potent compounds in an animal model. All statins (except pravastatin) inhibited intracellular Ras protein translocation. In summary, substantial tumor‐suppressive effects of various statins on the progression of experimental pancreatic adenocarcinoma were demonstrated, with marked differences among individual statins. These results support greatly the potential of statins for the chemoadjuvant treatment of pancreatic cancer. © 2007 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.23242

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Gbelcová, H., Leníček, M., Zelenka, J., Knejzlík, Z., Dvořáková, G., Zadinová, M., Poučková, P., Kudla, M., Balaž, P., Ruml, T., & Vítek, L.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2007-11-20
Volume
122
Issue
6
Pages
1214-1221
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2072703569
Cited by
110
References
3
FWCI
1.50
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.